title: [METHODOLOGIC PROBLEMS OF SENTINEL LYMPH NODE BIOPSY IN PATIENTS WITH BREAST CANCER].
abstract: The study included data on 168 patients with breast cancer, surgical treatment of whom was supplemented by axillary dissection (133 patients or 79.2%) or biopsy of sentinel lymph nodes (35 patients or 20.8%). The examination included ultrasound, planar scintigraphy of the breast and zones of regional lymph drainage. In 122 patients with primary breast cancer stage cT1-2N0M0 retrospective analysis of radionuclide imaging sentinel lymph node was performed. In 89 patients the introduction of colloidal radiopharmaceutical was carried out using a particle diameter of not more than 80-100 nm, in 33 patients study was conducted after administration of radiocolloid with a particle diameter of 200 to 1000 nm. Based on the data obtained by scintigraphy and ultrasonography of zones of regional lymph drainage there were offered two diagnostics models: the first, in which the presence of metastatic axillary lymph nodes was established when there were changes according to at least one of the diagnostic methods--scintigraphy or ultrasound; the second, in which the defeat of lymph nodes was determined only in the case of simultaneous detection of ultrasound and scintigraphic evidence of axillary lymph nodes. Sensitivity, specificity, and overall accuracy of the combination of ultrasound and planar scintigraphy axillary lymph nodes using the first model accounted for 82.7%, 67.7% and 74.4%, respectively. In the second model, the specificity was 94.6%, sensitivity--56%. Rapid transport of radiopharmaceuticals from the injection site, a high gradient of radiopharmaceuticals accumulation in sentinel lymph nodes, effective their visualization, approaching to 100%, were undoubted advantages of radiocolloids having a particle diameter up to 100 nm.
authors.forename: P V
authors.initials: PV
authors.lastname: Krivorotko
authors.forename: S V
authors.initials: SV
authors.lastname: Kanaev
authors.forename: V F
authors.initials: VF
authors.lastname: Semiglazov
authors.forename: S N
authors.initials: SN
authors.lastname: Novikov
authors.forename: P I
authors.initials: PI
authors.lastname: Krzhivitsky
authors.forename: I I
authors.initials: II
authors.lastname: Semenov
authors.forename: E A
authors.initials: EA
authors.lastname: Turkevich
authors.forename: E A
authors.initials: EA
authors.lastname: Busko
authors.forename: R V
authors.initials: RV
authors.lastname: Donskikh
authors.forename: Zh V
authors.initials: ZhV
authors.lastname: Bryantseva
authors.forename: E A
authors.initials: EA
authors.lastname: Piskunov
authors.forename: E S
authors.initials: ES
authors.lastname: Trufanova
authors.forename: A V
authors.initials: AV
authors.lastname: Chernaya
mesh_terms: D000328:Adult; D000368:Aged; D001365:Axilla; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery*; D003102:Colloids; D005260:Female; D006801:Humans; D008197:Lymph Node Excision; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery*; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008875:Middle Aged; D009367:Neoplasm Staging; D010316:Particle Size; D011237:Predictive Value of Tests; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D016217:Ultrasonography, Mammary
chemical_list: D003102:Colloids; D019275:Radiopharmaceuticals